medicine-news-1/study-details-swine-flu-transmission-rates--55637-1/;msg90356

Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2 Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4 YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5 Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6

[0] Lotus Pharmaceuticals, Inc. Appoints OTC Division Head [0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES [0] Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner [0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain

Breaking Medicine Technology:RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2 Dynatronics Receives 180-Day NASDAQ Extension 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2 Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3 Congressional Health Reform Bill Falls Short on Comprehensive and Affordable Coverage for Low Income Children 61194 1 Congressional Health Reform Bill Falls Short on Comprehensive and Affordable Coverage for Low Income Children 61194 2 Congressional Health Reform Bill Falls Short on Comprehensive and Affordable Coverage for Low Income Children 61194 3 Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 1 Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 2 Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 3 Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 4 Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 5 Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization 14801 6 Dynatronics to Release First Quarter Results Friday November 13 2009 3B Conference Call Set for 1 3A30 p m ET 6188 1

[0] RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793)[0] Dynatronics Receives 180-Day NASDAQ Extension [0] Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug